A breakthrough mRNA cancer therapy called intismeran autogene, built on COVID-19 vaccine tech, is showing massive promise in stopping melanoma from returning. In a landmark Phase 3 trial with over 1,000 patients, the personalized treatment—tailored to each tumor’s genetic code and paired with standard immunotherapy—significantly reduced recurrence and spread. Backed by Merck and Moderna, the results sent stocks soaring and mark the first major success of mRNA in large-scale cancer trials. Researchers are now preparing to present full data and seek approval, with plans to expand this approach to other cancers like lung, bladder, and kidney. This could redefine post-surgery cancer care and prove science’s power to repurpose innovation for life-saving breakthroughs.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
